Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin

In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding. This study sought to explore the effects o...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of the American College of Cardiology Ročník 74; číslo 12; s. 1519
Hlavní autoři:	Eikelboom, John W, Bosch, Jacqueline J, Connolly, Stuart J, Shestakovska, Olga, Dagenais, Gilles R, Hart, Robert G, Leong, Darryl P, O'Donnell, Martin, Fox, Keith A A, Bhatt, Deepak L, Cairns, John A, Tasto, Christoph, Berkowitz, Scott D, Cook Bruns, Nancy, Muehlhofer, Eva, Diaz, Rafael, Maggioni, Aldo P, Yusuf, Salim
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 24.09.2019
Témata:	Aged Aspirin - administration & dosage Aspirin - adverse effects Coronary Artery Disease - complications Drug Combinations Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Female Hemorrhage - chemically induced Humans Male Peripheral Arterial Disease - complications Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Rivaroxaban - administration & dosage Rivaroxaban - adverse effects Severity of Illness Index coronary artery disease dual pathway aspirin rivaroxaban bleeding peripheral artery disease
ISSN:	1558-3597, 1558-3597
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!